Compare Ascendis Pharma A/S (ASND) vs Norwegian Cruise Line Holdings Ltd (NCLH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Norwegian Cruise Line Holdings Ltd — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Norwegian Cruise Line Holdings Ltd trades at $19.52 (market cap $9.00B). The key difference: Ascendis Pharma A/S is the larger of the two by market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Norwegian Cruise Line Holdings Ltd nearer its low. Which is the better fit depends on your goals.
| ASND | NCLH | |
|---|---|---|
Market Cap | $17.74B | $9.00B |
Sector | Health | Consumer Cyclical |
52-Week High | $277.18 | $26.94 |
52-Week Low | $163.32 | $14.79 |
Enterprise Value | $18.11B | $23.97B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Norwegian Cruise Line Holdings (NCLH) trades at $19.61, down 0.76% on the day, with technical indicators showing a neutral to bearish bias amid recent volatility. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.23 surpassing expectations of $0.15, while revenue reached $9.83 billion in 2025. Analyst sentiment remains largely positive with a consensus price target of $22.06, though high debt levels and macroeconomic sensitivities present ongoing risks.
NCLH offers potential upside based on earnings momentum and favorable valuation multiples, but investors face headwinds from elevated leverage and industry-specific volatility. The stock's near-term direction hinges on Q2 2026 earnings delivery and sustained travel demand amid fluctuating fuel costs and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Norwegian Cruise Line Holdings Ltd
Norwegian Cruise Line is the world's third-largest cruise company by berths (at more than 62,000), operating 29 ships across three brands (Norwegian, Oceania, and Regent Seven Seas), offering both freestyle and luxury cruising. The company has redeployed its entire fleet as of May 2022. With eight passenger vessels on order among its brands through 2027 (representing 20,000 incremental berths), Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sailed to around 500 global destinations before the pandemic.
Read more on NCLH →
